Oncolytics Biotech Inc ONCY

ONCY's pelareorep can provide a fine T-cell boost for ADCs

[Noteable]

Further to Dr. Vile's specific comment to direct question on pelareorep and ADCs during the June 5th KOL meeting.

[Noteable]

Pelareorep's ability to remodel an otherwise immunosuppressive tumor microenvironment (TME), along with pelareorep's ability to 'prime' the innate and adaptive immune system, and pelareorep's  'fine' boosting capability are mechanisms that benefit the enhancement of both anti-body drug conjugates (ADC) and CAR-T therapies thus making both Pfizer and Roche

[Noteable]

And then there is the matter of pelareorep boosting ADCs which Dr. Vile stated would be very "synergistic". So first Immune checkpoint inhibitors, then CAR-T and now ADCs. Those are the increasing wonders of pelareorep.

[askretka]

I guess ADC's are a hot item probably because they have huge databases of antibodies they can draw from that they can use? There is a bad potential side effect of ADCs sometimes though. "As a class, ADCs are often associated with ophthalmic AEs, perhaps because of the robust blood supply, rapidly dividing cell populations, and abundant and variable receptors present in the eye (39

[Noteable]

Repost from June 06, 2023 -  " And then there is the matter of pelareorep boosting ADCs which Dr. Richard Vile stated would be very "synergistic". So first Immune checkpoint inhibitors, then CAR-T and now ADCs. Those are the increasing wonders of pelareorep."

[Noteable]

Now ADCs have been formally recogized as another therapy for use in combination with ONCY's pelareorep

[Noteable]

Potentially Pfizer/Seagen but not necessarily Roche https://www.fiercepharma.com/pharma/what-practice-changing-polivy-fda-challenges-roche-drug-ahead-lymphoma-expert-hearing 

[Noteable]

Further to Dr. Vile's specific comment to direct question on pelareorep and ADCs during the June 5, 2023 KOL meeting. Pelareorep's ability to remodel an otherwise immunosuppressive tumor microenvironment (TME), along with pelareorep's ability to 'prime' the innate and adaptive immune system, and pelareorep's  'fine' boosting capability are mechanisms that

[Noteable]

ADCs will face challenges, such as complex pharmacokinetics, side effects, narrow tumor targeting, tumor penetration  and drug resistance.  Since February 2024, the FDA has given 12 ADCs approval for several different cancers, including lymphomas, leukemia, myeloma, and solid tumors, such as HER2+ breast cancer, urothelial cancer, metastatic triple-negative breast cancer

[Noteable]

In February 2024, AbbVie closed a $10.1 billion deal acquiring ImmunoGen, an ADC-focused biotechnology company headquartered in suburban Boston. With the agreement, AbbVie gained Elahere (mirvetuximab soravtansine), the only ADC approved by the FDA as a treatment for ovarian cancer. 

[JohnnyYeg]

And for those that "comment" on the fact ONCY has been around for 25 years and has "nothing to show",  ImmunoGen has been around for 40 years...

[Noteable]

In February 2024, AbbVie closed a $10.1 billion deal acquiring ImmunoGen, an ADC-focused biotechnology company headquartered in suburban Boston.  June 07, 2024 - Abbive reported on the Phase II PICCOLO trial from its newly acquired antibody-drug conjugate Elahere (mirvetuximab soravtansine) from ImmunoGen in folate receptor-alpha-positive, platinum-sensitive ovarian cancer. 

[Noteable]

 ImmunoGen has been around for 40 years ... before being acquired by Abbive this year for US$10.1 Billion.

[inthno]

Doing comparisons it would be nice if onc is being considered for a BO as opposed to a partnership as it ends all uncertainty surrounding the company. As to IMmunoGEn, I believe that they were worth in the billions before being acquired from looking at ther chart so hard to compare that with onc which at this time is trading under 100 million U.S. I think most would be happy if we got anything

[Noteable]

ImmuoGen's only approval occurred in November 2022, for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinumresistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. ImmunoGen's other solid cancer candidates are either pre-clinical or in Phase 1 stages. Consequently, ONCY'

[Noteable]

ImmuoGen's only approval occurred as an Accelerated Approval in November 2022. Their follow-on confirmatory trial is  MIRASOL: Monotherapy in FRα-High Platinum-Resistant Ovarian Cancer (Randomized Confirmatory Trial) POSITIVE TOP-LINE DATA REPORTED MAY 2023 MIRASOL: Monotherapy in FRα-High Platinum-Resistant Ovarian Cancer (Randomized Confirmatory Trial) POSITIVE TOP-LINE DATA

[Noteable]

Challenges Faced by Antibody-Drug Conjugates Potential cancer resistance to ADCs Cancer cells can gradually develop mechanisms to resist ADCs, reducing their effectiveness over time. This resistance may arise from various factors, including altered target cell surface expression or gene mutation, resistance to the ADC payload, failure in internalisation processes